

## OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China

Drug Week, February 27, 2009 - **OriGene** Technologies, Inc. ("OriGene") announced it has raised an additional \$6.5 million in a private equity financing. With this financing, OriGene completed the acquisition of the assets of privately held Shenzhen P & A Biotech, a manufacturer and provider of monoclonal antibodies (mAb) to the research community. With this acquisition OriGene completes the establishment of its technology center to develop genome-wide monoclonal antibodies to all human proteins (see also Monoclonal Antibodies).

Over the last ten years OriGene has developed the capacity to produce thousands of human full-length proteins from human cells. These human cell produced human proteins are ideal antigens for high throughput monoclonal antibody production. During the last two years, OriGene also has developed a genome wide collection of antigen standards and over 100,000 tissue samples that are ideal tools for high quality antibody validation. With OriGene's China monoclonal antibody production capacity and these unique genome-wide resources OriGene believes it can produce several thousand high quality monoclonal antibodies per year.

This genome-wide mAb production capacity is available to all commercial and academic partners with a long-term goal to providing high quality monoclonal antibodies for every single human gene.